Clinical trial · Interventional
Safety and Efficacy of γδ T Cell Against Gastric Cancer
γδ T Cell Immunotherapy for Treatment of Gastric Cancer
NCT02585908CI-TRIAL-00041601unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, safety and effects of γδT cells on human gastric cancer are going to be investigated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CIK | Biological | — | UNRESOLVED |
| CIK and γδ T | Biological | — | UNRESOLVED |
| γδ T | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- NO_INTERVENTION
- label
- Experimental Group A(control group)
- description
- regular treatment and follow up
- type
- EXPERIMENTAL
- label
- Experimental Group B
- description
- CIK will be used against tumor cells.
- interventionNames
- Biological: CIK
- type
- EXPERIMENTAL
- label
- Experimental Group C
- description
- γδ T will be used against tumor cells.
- interventionNames
- Biological: γδ T
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age:30-75 2. Karnofsky performance status \>50 3. Diagnosis with gastric cancer based on histology or the current accepted radiological measures. 4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ 5. Patients who have a life expectancy of at least 12 weeks 6. Ability to understand the study protocol and a willingness to sign a written informed consent document Exclusion Criteria: 1. Any significant medical or psychiatric illness that would prevent the patient from giving informed consent or from following the study procedures. 2. Known human immunodeficiency virus (HIV) infection. 3. Active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection). 4. Other serious underlying medical conditions, which, in the Investigator's judgment, could impair the ability of the patient. 5. Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.